Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term Debt
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed N.V (MYNZ) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Mainz Biomed N.V (MYNZ) over the last 1 years, with Jun 2025 value amounting to $6.0 million.

  • Mainz Biomed N.V's Total Current Liabilities fell 40.20% to $6.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.0 million, marking a year-over-year decrease of 40.20%. This contributed to the annual value of $5.9 million for FY2024, which is 35.59% down from last year.
  • According to the latest figures from Q2 2025, Mainz Biomed N.V's Total Current Liabilities is $6.0 million, which was up 0.65% from $5.9 million recorded in Q4 2024.
  • Over the past 5 years, Mainz Biomed N.V's Total Current Liabilities peaked at $11.3 million during Q3 2023, and registered a low of $1.4 million during Q4 2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $9.2 million (2023), whereas its average is $8.6 million.
  • As far as peak fluctuations go, Mainz Biomed N.V's Total Current Liabilities surged by 332.90% in 2023, and later plummeted by 40.20% in 2025.
  • Quarterly analysis of 5 years shows Mainz Biomed N.V's Total Current Liabilities stood at $1.4 million in 2021, then spiked by 213.86% to $4.2 million in 2022, then surged by 117.72% to $9.2 million in 2023, then slumped by 35.59% to $5.9 million in 2024, then tumbled by 40.20% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q2 2025, $5.9 million for Q4 2024, and $10.0 million during Q2 2024.